Intraarticular corticosteroid injections in pediatric rheumatology: insights from specialists

Çisem Yıldız1, Batuhan Küçükali2, Sushma Shree B C3

  • 1Department of Pediatric Rheumatology, Faculty of Medicine, Gazi University, 06560, Besevler Ankara, Turkey. cisemyildiz@hotmail.com.

PubMed

Insights

Intraarticular corticosteroid injections (IACIs) are common for juvenile idiopathic arthritis (JIA), but practices vary widely among pediatric rheumatologists. Standardized protocols are needed to improve treatment efficacy and patient outcomes.

Area of Science:

  • Pediatric Rheumatology
  • Clinical Practice Guidelines
  • Arthritis Management

Background:

  • Intraarticular corticosteroid injections (IACIs) are effective for juvenile idiopathic arthritis (JIA), offering symptom relief and preventing joint deformities.
  • However, significant variability exists in IACI indications, techniques, and anesthesia methods among pediatric rheumatologists, with much evidence being anecdotal.

Purpose of the Study:

  • To compare intraarticular corticosteroid injection (IACI) strategies used by pediatric rheumatologists in Turkey and India.
  • To identify variations in IACI practices, including agents, dosages, sites, follow-up, complications, anesthesia, and post-injection treatments.

Main Methods:

  • A cross-sectional survey using a 33-item questionnaire distributed via Google Forms to pediatric rheumatologists in Turkey and India.
  • Analysis of responses from 70 clinicians regarding their IACI practices for juvenile idiopathic arthritis (JIA).

Main Results:

  • All surveyed clinicians use IACIs, primarily for oligoarticular JIA (100%).
  • Triamcinolone hexacetonide (74.3%) was the preferred agent, often targeting the knee (15.7%). Common complications included hypopigmentation and atrophy. Ketamine was the favored anesthetic (44.2%).
  • Significant practice variations were observed in ultrasound guidance use (17.1%) and post-IACI treatment strategies.

Conclusions:

  • Intraarticular corticosteroid injections (IACIs) are a widely adopted treatment for oligoarticular juvenile idiopathic arthritis (JIA), but considerable practice variability persists.
  • Standardized protocols, informed by further research and randomized studies, are essential to optimize IACI efficacy and improve patient outcomes in JIA management.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
224
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117